Largest private Biotech investment since 2001

The immatics management (from left to right): Jrgen freshness, M.D., Jrg Scheidle, Harpreet Singh, Ph.D and Niels Emmerich, Ph.D. - 40 million euro for immatics the biotechnologies GmbH from Tbingen in the second financing round.

(Stuttgart/Tbingen) - immatics the biotechnologies GmbH took the conclusion of their second financing round on 8 February of yesterday to the cause, in order to inform at the Finanzplatz Frankfurt/Main about this private Biotech investment largest with 40 million euro in Germany since the year 2001. New Lead investor, the Immuntherapeutika for the cancer treatment of specialized biopharmaceutical enterprise, Peptid based on the development, is the SAP joint founder Dietmar Hopp. Beside existing consortium, which Wellington of partner, 3i, which belongs to Grazia Equity GmbH, L-EA/SEED, Merifin Capital, embl ventures and Swiss Vinci Capital Renaissance, those knew national Technology Enterprises company (NTEC) and the KfW is won as new CO investors.

The Innovationspotenzial immatics the biotechnologies GmbH had already arranged the past Lead investor Wellington of partner and 3i 2004 to invest into the enterprise. We see ourselves confirmed in the fact that immatics a prominent platform technology offers and has therefore again invested, says Professor Erich mud, general partner with Wellington of partner. Quality, development and market chances of the first product candidates of immatics convinced also us, say Dr. Friedrich von Bohlen and Halbach of the Heidelberger Dievini advisors into health sciences GmbH & CO kg, which advises Dietmar Hopp with the selection and structuring of its Investments in Life Sciences. The new Lead investor Hopp impress on immatics the immunological-medical beginning, the one causal fight against cancer make possible as well as the broadly set up and removable pipeline of product candidates and the business authority of the acting persons, explained from planks and halfoh. Still, particularly in the USA, the German Biotech industry is noticed not as equal, but quality and Potenzial to have in the meantime world level. The local Biotech scene is just as progressive and competitive as the American.

That immatics the new financing round in this order of magnitude locked, underlines, says the increasing meaning of biotechnological products also from the view of important decision makers from the industry Dr. Klaus oak mountain, managing director of the BioRegio STAR management GmbH. The straight commitment of Dietmar Hopp has large signal effect.

The product candidates of immatics are based on tumor-associated Peptiden so mentioned (TUMAPs), which stimulate the immune system against cancer cells. Up-to-date the enterprise successfully locked the phase 1 of the clinical development for the therapeutic active substance IMA901. The second product candidate IMA910 for the treatment of intestine cancer is to come still in this year into the hospital. The clinical phase 2-Studien for both product candidates should be terminated to 2009; two further active substance candidates for the treatment of stomach and cancer of the lungs are to occur up to then the phase 1 of clinical examinations.

Supported of the past and the new investors we want to drive the establishment of our Peptid based vaccines cancer therapies future as column briskly in front, say Dr. Niels Emmerich, managing director immatics the biotechnologies GmbH. The new financial volume makes it for us possible to lock not only the clinical studies faster to remove but also our product pipeline for further innovative Immuntherapeutika. For 2010 and/or 2011 plan we, first applications for admission for Europe, Japan, to submit North America and different developing countries with the Food and Drug administration (FDA) and the European medicament agency EMEA.
zk-big

Publisher:
BioRegio STAR management GmbH, Friedrichstrasse 10, 70174 Stuttgart, 0711-8703540, info@bioregio-stern.de
Editorship: Zeeb communication, Hohenheimer road 58a, 70184 Stuttgart, 0711-6070719, info@zeeb.info

immatics biotechnologies GmbH:
Dr. Niels Emmerich, Paul Ehrlich road 15, 72076 Tbingen, 07071-5651250, emmerich@immatics.com

Over BioRegio STAR:
In the region of Baden-Wuerttemberg Stuttgart, Tbingen, Esslingen, Reutlingen and Neckar Alb the BioRegio STAR management GmbH is common authority network, approach and advisory board for existence founders, entrepreneurs and researchers in the range biotechnology. BioRegio STAR promotes the co-operation of most different disciplines such as medicine, process technique, sensor technology, nourishing science, biochemical analytics and bio computer science. Regeneration biology forms an important emphasis.

BioRegio STAR represents the interests of the existence founders, entrepreneurs and researchers in relation to politics, media and federations, bundles promotion of economy development and marketing, advises with promotion requests and Unternehmensfinanzierungen and supports this work by an engaged pressing and public work.

BioRegio STAR supported of the Federal Ministry for education and research (BMBF) in the context of the advancement program of bio profiles, the regions Stuttgart and Neckar Alb as well as the cities Stuttgart, Tbingen, Esslingen and Reutlingen. Managing director is the molecular and cell biologist and Investmentanalyst Dr. Klaus oak mountain.

Over immatics the biotechnologies GmbH:
In the year 2000 the created immatics biotechnologies GmbH is an independent biopharmaceutical enterprise with seat in the university town Tbingen. With own technologies identify and validate immatics new active substances for the treatment of different cancer illnesses. The active substances consist of short Peptiden for the Stimulation of body-own cells of the human immune system against Tumore. Apart from the rapid clinical development for the indication kidney cell cancer is the description of further tumor antigens relevant for the immune therapy in connection with particularly frequent cancer illnesses of central importance for immatics.

Dieser Artikel wurde veröffentlicht auf